Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Loxapine film - IntelGenx

Next Previous
Search
Drug Profile

Loxapine film - IntelGenx

Alternative Names: INT 0036/2012; INT 0036/2013; INT0036; Loxapine VersaFilm®

Latest Information Update: 23 Feb 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IntelGenx Corp.
  • Class Antipsychotics; Dibenzoxazepines; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

Most Recent Events

  • 21 Feb 2023 IntelGenx receives notice of allowance for a patent covering the use of loxapine oral film formulations in patients with anxiety and agitation associated with schizophrenia and bipolar 1 disorder, in USA
  • 31 Dec 2020 Suspended - Clinical-Phase-Unknown for Schizophrenia in Canada (PO)
  • 24 Feb 2020 Loxapine film is still in clinical development for the treatment of Schizophrenia (IntelGenx pipeline, February 2020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top